down arrow

NextCure, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US65343E1082
USD
12.73
0.18 (1.43%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

12.0013.44

52 Week

2.6915.61
Valuation
Technical
Day's Volume

CASH

32.24 k

Shareholding (Mar 2025)

FII

3.12%

Held by 15 FIIs

DII

69.34%

Held by 9 DIIs

Promoter

20.41%

How big is NextCure, Inc.?

22-Jun-2025

As of Jun 18, NextCure, Inc. has a market capitalization of 12.66 million, with net sales of 0.00 million and a net profit of -49.52 million over the latest four quarters. Shareholder's funds are 65.47 million, and total assets are 81.92 million as of Dec 24.

As of Jun 18, NextCure, Inc. has a market capitalization of 12.66 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 0.00 million, while the sum of Net Profit for the same period is -49.52 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds of 65.47 million and Total Assets of 81.92 million.

Read More

What does NextCure, Inc. do?

22-Jun-2025

NextCure, Inc. is a clinical-stage biopharmaceutical company focused on developing immunomedicines for cancer and immune-related diseases, with a market cap of $12.66 million and a recent net profit of -$11 million. The company operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap firm.

Overview:<BR>NextCure, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing immunomedicines to treat cancer and other immune-related diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -11 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 12.66 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -0.98<BR>Return on Equity: -88.66%<BR>Price to Book: 0.23<BR><BR>Contact Details:<BR>Address: 9000 Virginia Manor Rd Ste 200, BELTSVILLE MD: 20705-4214<BR>Tel: 1 240 3994900<BR>Website: http://www.nextcure.com/

Read More

Who are in the management team of NextCure, Inc.?

22-Jun-2025

As of March 2022, the management team of NextCure, Inc. includes Dr. David Kabakoff (Independent Chairman), Mr. Michael Richman (President and CEO), Dr. John Houston, Ms. Elaine Jones, Mr. Chau Khuong, Dr. Briggs Morrison, and Mr. Garry Nicholson, all serving as directors. This team oversees the company's strategic direction and operations.

As of March 2022, the management team of NextCure, Inc. includes the following individuals:<BR><BR>- Dr. David Kabakoff, who serves as the Independent Chairman of the Board.<BR>- Mr. Michael Richman, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. John Houston, who is a Director.<BR>- Ms. Elaine Jones, who is an Independent Director.<BR>- Mr. Chau Khuong, who is also an Independent Director.<BR>- Dr. Briggs Morrison, who serves as an Independent Director.<BR>- Mr. Garry Nicholson, who is another Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Read More

Is NextCure, Inc. overvalued or undervalued?

25-Jun-2025

NextCure, Inc. is currently considered overvalued with a valuation downgrade to "does not qualify" due to negative financial metrics, including a Price to Book Value of 0.25, an EV to EBITDA of 0.82, and a concerning ROE of -88.66%, alongside poor stock performance of -39.04% year-to-date compared to the S&P 500's positive return.

As of 6 May 2021, the valuation grade for NextCure, Inc. has moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company is currently considered overvalued, primarily due to its negative financial metrics. The P/E ratio is not applicable as the company is loss-making, while the Price to Book Value stands at 0.25, and the EV to EBITDA is at 0.82. Additionally, the ROE is a concerning -88.66%, highlighting the company's struggles to generate returns.<BR><BR>In comparison to its peers, NextCure's valuation metrics are less favorable. For instance, Rezolute, Inc. has an EV to EBITDA of -3.4613, and SELLAS Life Sciences Group, Inc. shows an EV to EBITDA of -4.5726, both indicating significant challenges in profitability. The company's recent stock performance has also been poor, with a year-to-date return of -39.04%, contrasting sharply with the S&P 500's positive return of 2.44% during the same period. This further reinforces the view that NextCure is overvalued in the current market context.

Read More

Is NextCure, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, NextCure, Inc. has a mildly bullish trend supported by weekly indicators, despite short-term bearish signals, and has outperformed the S&P 500 recently but underperformed year-to-date.

As of 10 September 2025, the technical trend for NextCure, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by the weekly MACD and KST indicators, both showing mild bullishness, while the monthly RSI is bullish. However, the daily moving averages are mildly bearish, indicating some short-term weakness. The Bollinger Bands present a mixed view with a bullish weekly signal but a mildly bearish monthly signal. Overall, the indicators suggest a cautious bullish outlook.<BR><BR>In terms of performance, NextCure has outperformed the S&P 500 over the past week and month, with returns of 3.98% and 7.54% respectively, but has significantly underperformed over longer periods, with a year-to-date return of -38.86% compared to the S&P 500's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 13 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.10

stock-summary
Return on Equity

-192.53%

stock-summary
Price to Book

0.42

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-27 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
155.62%
0%
155.62%
6 Months
123.95%
0%
123.95%
1 Year
-6.12%
0%
-6.12%
2 Years
-11.6%
0%
-11.6%
3 Years
802.84%
0%
802.84%
4 Years
-81.45%
0%
-81.45%
5 Years
-90.31%
0%
-90.31%

NextCure, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is NextCure, Inc. technically bullish or bearish?

As of 10 September 2025, the technical trend for NextCure, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by the weekly MACD and KST indicators, both showing mild bullishness, while the monthly RSI is bullish. However, the daily moving averages are mildly bearish, indicating some short-term weakness. The Bollinger Bands present a mixed view with a bullish weekly signal but a mildly bearish monthly signal. Overall, the indicators suggest a cautious bullish outlook. In terms of performance, NextCure has outperformed the S&P 500 over the past week and month, with returns of 3.98% and 7.54% respectively, but has significantly underperformed over longer periods, with a year-to-date return of -38.86% compared to the S&P 500's 12.22%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-170.93%
EBIT to Interest (avg)
-61.28
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.98
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
71.56%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.25
EV to EBIT
0.77
EV to EBITDA
0.82
EV to Capital Employed
-41.04
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-88.66%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 10 Schemes (7.14%)

Foreign Institutions

Held by 15 Foreign Institutions (3.12%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -74.03% vs 13.97% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-26.70",
          "val2": "-15.80",
          "chgp": "-68.99%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-26.80",
          "val2": "-15.40",
          "chgp": "-74.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 11.16% vs 16.06% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-54.30",
          "val2": "-64.00",
          "chgp": "15.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.50",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-55.70",
          "val2": "-62.70",
          "chgp": "11.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-26.70
-15.80
-68.99%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-26.80
-15.40
-74.03%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -74.03% vs 13.97% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-54.30
-64.00
15.16%
Interest
0.00
0.00
Exceptional Items
-2.50
0.00
Consolidate Net Profit
-55.70
-62.70
11.16%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 11.16% vs 16.06% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About NextCure, Inc. stock-summary
stock-summary
NextCure, Inc.
Pharmaceuticals & Biotechnology
Nextcure Inc. is a clinical-stage biopharmaceutical company, which is focused on discovering and developing immunomedicines to treat cancer and other immune-related diseases. The Company uses its functional integrated nextcure discovery in immune oncology (FIND-IO) technology to functional screening approaches for the identification of targets from multiple therapeutic areas, including autoimmunity and neurology, enabling immunomedicine to treat unmet medical needs. Its product pipelines include NC318, a immunotherapeutic against a immunomodulatory target found on a restricted set of myeloid and tumor cells, and NC410, a immunomedicine designed to block an immune regulator expressed on T cells and suppressive antigen-presenting cell populations, including dendritic cell subpopulations.
Company Coordinates stock-summary
Company Details
9000 Virginia Manor Rd Ste 200 , BELTSVILLE MD : 20705-4214
stock-summary
Tel: 1 240 3994900
stock-summary
http://www.nextcure.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."